Dermapharm Holding SE, the German pharmaceutical company listed under ticker 0A5J, has issued a preliminary announcement confirming it will publish its third-quarter financial report on 12 November 2026. The disclosure was transmitted via EQS News on 5 November 2026 and covers the quarterly financial report within the second half of the company's financial year. The report will be made available in both German and English through Dermapharm's investor relations portal, giving investors across markets simultaneous access to the results.

Key Points

  • Dermapharm Holding SE (0A5J), headquartered in Grünwald, Germany, with LEI Code 5299009F0KNZINQQQK37
  • The company has confirmed publication of its Q3 2026 quarterly financial report, covering the second half-year period
  • Report due for disclosure on 12 November 2026 in both German and English simultaneously
  • Investors should monitor the company's IR portal at ir.dermapharm.de for the full report on the stated date

Dermapharm Holding SE Schedules Q3 Report Release for 12 November 2026

The announcement, issued through EQS News on 5 November 2026 at 14:00 CET, confirms that Dermapharm Holding SE will disclose its quarterly financial report for the third quarter of 2026 on 12 November 2026. This report forms part of the company's second half-year reporting cycle. Dermapharm Holding SE is a Germany-based pharmaceutical group headquartered at Lil-Dagover-Ring 7, Grünwald, and operates primarily in the development, manufacturing, and distribution of branded pharmaceutical products, focusing on markets where it holds established product licences.

Bilingual Publication Signals Dermapharm's Commitment to International Investor Access

The Q3 2026 report will be published simultaneously in both German and English, reflecting Dermapharm's approach to transparent communication with its international investor base. The German-language report and the English-language version will both be accessible via the company's dedicated investor relations portal at ir.dermapharm.de on 12 November 2026. This dual-language release ensures that non-German-speaking shareholders and analysts can access the same financial information at the same time as domestic investors, reducing informational asymmetry ahead of any market reaction to the results.

What the Q3 2026 Disclosure Means for Dermapharm Investors Watching Second-Half Performance

As a quarterly financial report covering the third quarter within the second half of Dermapharm's financial year, the forthcoming disclosure will provide investors with an updated view of the company's operational and financial performance during that period. No financial figures, revenue guidance, or profit metrics were included in this preliminary announcement, as it serves solely as advance notification of the reporting date. Investors and analysts tracking Dermapharm's pharmaceutical product pipeline, licensing arrangements, and German market revenues will need to wait for the full report on 12 November 2026 to assess the company's progress.